ELP1 and Fabry disease: We further validated the effects of compound treatment (RECTAS, TG003, INDY, CaNDY, ALGERNON, and SRPIN340) and knockdown of SRSF6 or CLK in FD patient fibroblasts with the homozygous IKBKAP-FD IVS20 + 6 T > C mutation, and confirmed the increased IKBKAP-FD exon 20 skipping by CLK inhibition (Fig. 2g and Supplementary Fig. 1a) or depletion for SRSF6 or CLK (Fig. 2h and Supplementary Fig. 2a) for the endogenous transcripts.